KMTS

+ Watchlist + Portfolio

Kestra Medical Technologies, Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $27.91
52-Week Range: $15.42 – $30.00
Market Cap: $1.60B
P/E (TTM): —
EPS (TTM): -2.43
Dividend Yield: —

Advanced Metrics

Price/Book: 6.13
PEG Ratio: —
Return on Equity: -56.60%
Return on Assets: -25.75%
Gross Margin: 51.37%
Operating Margin: -137.38%
Profit Margin: -138.35%
Current Ratio: 4.41
Debt/Equity: 0.18
Total Debt: $46.79M
Free Cash Flow: $-75.76M
Revenue Growth: 66.20%
Earnings Growth: —
Enterprise Value: $1.49B

KMTS Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$7.63M	$27.81M	$59.81M	$95.13M
Cost of Revenue	$18.28M	$27.45M	$35.60M	$46.26M
Gross Profit	-$10.65M	$362.00K	$24.21M	$48.86M
Research & Development	$15.76M	$15.49M	$15.65M	$19.48M
Selling, General & Admin	$54.01M	$69.94M	$114.94M	$164.12M
Operating Expenses	$69.77M	$85.42M	$130.59M	$183.60M
Operating Income	-$80.42M	-$85.06M	-$106.38M	-$134.74M
EBITDA	-$73.74M	-$76.31M	-$97.98M	-$115.06M
Pretax Income	-$84.22M	-$94.10M	-$113.68M	-$131.32M
Income Tax	$15.00K	$24.00K	$135.00K	$294.00K
Net Income	-$84.24M	-$94.12M	-$113.81M	-$131.61M
Diluted EPS	-4.36	-5.07	-5.13	—
Diluted Shares	19.89M	19.89M	24.58M	—

KMTS Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$14.81M	$8.25M	$237.59M	$99.71M
Receivables	$0.00	$2.00M	$8.08M	$14.54M
Inventory	$2.11M	$3.29M	$6.57M	$6.71M
Current Assets	$18.42M	$14.91M	$255.33M	$222.36M
Total Assets	$38.66M	$45.95M	$295.74M	$358.46M
Current Liabilities	$36.74M	$32.97M	$37.98M	$50.37M
Long-Term Debt	$17.32M	$42.54M	$41.10M	$42.65M
Total Debt	$39.13M	$45.17M	$44.31M	$46.79M
Total Liabilities	$156.23M	$255.33M	$90.34M	$98.81M
Retained Earnings	-$312.31M	-$406.44M	-$520.25M	-$651.86M
Shareholders' Equity	-$117.58M	-$209.38M	$205.41M	$259.66M
Working Capital	-$18.32M	-$18.06M	$217.35M	$171.99M
Net Debt	$22.96M	$34.29M	—	—

KMTS Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$69.64M	-$72.23M	-$77.61M	-$81.70M
Capital Expenditure	-$15.46M	-$12.51M	-$23.59M	-$35.42M
Free Cash Flow	-$85.10M	-$84.75M	-$101.20M	-$117.12M
Depreciation & Amortisation	$4.86M	$11.56M	$7.97M	$8.71M
Stock-Based Compensation	$1.21M	$1.49M	$24.27M	$33.64M
Investing Cash Flow	-$15.46M	-$12.23M	-$23.31M	-$203.28M
Financing Cash Flow	$96.11M	$77.72M	$330.26M	$147.09M
Dividends Paid	-$671.00K	-$799.00K	-$1.65M	-$323.00K
Net Change in Cash	$11.00M	-$6.74M	$229.35M	-$137.88M

KMTS Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$17.23M	$19.37M	$22.57M	$24.55M	$28.64M
Cost of Revenue	$9.60M	$10.52M	$11.14M	$11.65M	$12.96M
Gross Profit	$7.63M	$8.85M	$11.42M	$12.91M	$15.68M
Research & Development	$5.39M	$4.00M	$4.88M	$4.97M	$5.63M
Selling, General & Admin	$50.46M	$33.73M	$38.30M	$42.70M	$49.39M
Operating Expenses	$55.84M	$37.73M	$43.18M	$47.67M	$55.03M
Operating Income	-$48.21M	-$28.88M	-$31.75M	-$34.77M	-$39.34M
EBITDA	-$47.41M	-$21.85M	-$28.48M	-$30.26M	-$34.47M
Pretax Income	-$51.01M	-$25.79M	-$32.75M	-$34.13M	-$38.64M
Income Tax	$102.00K	$33.00K	$34.00K	$35.00K	$192.00K
Net Income	-$52.05M	-$25.83M	-$32.78M	-$34.17M	-$38.84M
Diluted EPS	-2.21	-0.50	-0.64	-0.61	-0.67
Diluted Shares	24.58M	51.30M	51.38M	55.85M	58.40M

KMTS Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$237.59M	$201.21M	$175.42M	$291.32M	$99.71M
Receivables	$8.08M	$9.25M	$10.41M	$12.71M	$14.54M
Inventory	$6.57M	$6.80M	$6.92M	$6.83M	$6.71M
Current Assets	$255.33M	$220.69M	$195.41M	$314.06M	$222.36M
Total Assets	$295.74M	$266.30M	$246.70M	$379.34M	$358.46M
Current Liabilities	$37.98M	$32.26M	$35.76M	$42.93M	$50.37M
Long-Term Debt	$41.10M	$41.49M	$41.87M	$42.26M	$42.65M
Total Debt	$44.31M	$44.59M	$44.80M	$46.55M	$46.79M
Total Liabilities	$90.34M	$82.14M	$82.62M	$91.35M	$98.81M
Retained Earnings	-$520.25M	-$546.08M	-$578.86M	-$613.03M	-$651.86M
Shareholders' Equity	$205.41M	$184.16M	$164.08M	$287.99M	$259.66M
Working Capital	$217.35M	$188.44M	$159.66M	$271.13M	$171.99M

KMTS Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$23.70M	-$26.27M	-$18.34M	-$18.37M	-$18.72M
Capital Expenditure	-$8.04M	-$8.27M	-$7.50M	-$9.99M	-$9.66M
Free Cash Flow	-$31.74M	-$34.54M	-$25.84M	-$28.35M	-$28.39M
Depreciation & Amortisation	$1.84M	$2.03M	$2.37M	$1.98M	$2.33M
Stock-Based Compensation	$22.31M	$4.58M	$8.65M	$10.11M	$10.30M
Investing Cash Flow	-$7.76M	-$8.23M	-$7.42M	-$14.92M	-$172.71M
Financing Cash Flow	$214.70M	-$1.88M	-$27.00K	$149.18M	-$185.00K
Dividends Paid	-$6.00K	$0.00	$0.00	-$25.00K	-$298.00K
Net Change in Cash	$183.24M	-$36.38M	-$25.79M	$115.90M	-$191.61M

Market Snapshot

About

Kestra Medical Technologies, Ltd. is a medical device company focused on developing innovative solutions for cardiovascular and vascular interventions. The company's technologies typically address unmet clinical needs in areas such as structural heart disease, peripheral vascular disease, or cardiac access procedures. Kestra Medical advances its products through clinical trials and regulatory pathways to bring minimally invasive treatment options to patients. The company collaborates with physicians and healthcare institutions to develop and commercialize its medical devices.